|
시장보고서
상품코드
2131211
남성 성선기능저하증 시장 규모, 점유율 및 성장 분석 : 성선기능저하증 유형별, 병인별, 치료 유형별, 투여 경로별, 진단별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Male Hypogonadism Market Size, Share, and Growth Analysis, By Type of Hypogonadism, By Etiology, By Treatment Type, By Route of Administration, By Diagnosis, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 남성 성선기능저하증 시장 규모는 2024년에 16억 5,000만 달러로 평가되며, 2025년 17억 7,000만 달러에서 2033년까지 31억 4,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 7.4%로 성장할 것으로 전망되고 있습니다.
전 세계 남성 성선 기능 저하증 시장은 테스토스테론 수치가 낮은 남성을 대상으로 한 진단, 호르몬 대체요법 및 지원 서비스를 둘러싼 상업적 상황을 포괄합니다. 이 시장은 성선 기능 저하증이 삶의 질, 심혈관 건강 및 생산성에 미치는 큰 영향에 의해 주도되고 있습니다. 경피 흡수형 젤이나 경구 제제 등 혁신적인 치료법의 도입은 그 보급을 촉진하여, 이 틈새 시장을 의료 종사자들에게 가치 있는 분야로 탈바꿈시켰습니다. 주요 성장 요인으로는 제품 혁신과 보험 환급 전략을 촉진하는 맞춤형 의료의 통합을 들 수 있습니다. 또한 AI를 활용한 진단 자동화를 통해 식별 및 관리 프로세스가 효율화되어 조기 개입과 치료 성과 향상이 도모되고 있습니다. 그 결과, 호르몬 대체요법 제품에 대한 수요가 촉진되는 동시에, 의료 시스템에 비용 대비 효과가 높은 진단 솔루션이 제공되고 있습니다.
전 세계 남성 성선 기능 저하증 시장의 성장 요인
테스토스테론 수치 저하에 따른 증상에 대한 일반 대중의 인식이 높아짐에 따라 의학적 평가를 원하는 남성이 증가하고 있습니다. 이러한 변화로 인해 진단율이 상승하고, 호르몬 대체요법의 대상이 되는 환자 수도 늘어나고 있으며, 그 결과 의약품 및 관련 헬스케어 서비스에 대한 수요가 확대되고 있습니다. 현재 의료 종사자들은 증상을 더 명확하게 인식하고 있으며, 이를 바탕으로 더 확신을 가지고 처방할 수 있게 되었습니다. 또한 환자 지원 단체는 남성의 호르몬 건강에 관한 솔직한 논의를 촉진하는 교육 자료를 제공함으로써 중요한 역할을 수행하고 있습니다. 이러한 움직임은 선순환을 만들어 인지도를 높이고 치료에 대한 수용성을 모두 향상시키며, 궁극적으로 전 세계 남성 성선기능저하증 시장의 지속적인 성장을 지원하고 있습니다.
전 세계 남성 성선 기능 저하증 시장의 제약 요인
테스토스테론 대체요법, 특히 지속형 주사제나 경피 흡수형 제제와 관련된 고비용은, 특히 보험 적용이 충분하지 않은 지역에서 많은 사람들에게 심각한 경제적 문제로 대두되고 있습니다. 이러한 비용 문제는 종종 높은 본인 부담금을 초래하여 환자가 지속적인 치료 계획을 유지하는 데 방해가 되며, 의료 서비스 제공자로 하여금 더 경제적인 대안을 모색하도록 촉진하고 있습니다. 그 결과, 임상의가 더 경제적인 처방 방법을 우선시할 가능성이 있으므로 이러한 비용에 대한 민감성이 시장 전반의 보급을 저해하고 있습니다. 또한 제약 기업은 가격 인하나 가치 기반 지불 모델을 도입하지 않는 한 판매량 확대를 도모하는 데 장벽에 직면하고 있으며, 이는 궁극적으로 시장 확대와 환자의 접근성을 제한하게 됩니다.
전 세계 남성 성선 기능 저하증 시장의 동향
전 세계 남성 성선 기능 저하증 시장에서는 개별 유전자 프로파일, 증상의 중증도, 생활 습관 요인에 맞춘 개인화된 치료 접근법을 특징으로 하는 정밀 호르몬 요법으로의 견고한 추세가 나타나고 있습니다. 임상의들은 호르몬 대체요법을 최적화하고, 부작용을 최소화하며, 환자의 복약 순응도를 높이기 위해 바이오마커 패널과 디지털 모니터링 기술을 점점 더 많이 도입하고 있습니다. 이러한 변화는 내분비 전문의, 불임 치료 전문가, 기술 혁신가 간의 협력을 촉진하고 있으며, 그 결과 환자 만족도를 높일 뿐만 아니라 의료 제공자에게 새로운 수익 기회를 창출하는 통합적인 치료 경로가 구축되고 있습니다. 궁극적으로, 이러한 맞춤형 치료 패러다임은 성선 기능 저하증 환자의 전반적인 삶의 질을 대폭 개선하는 것을 목표로 하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 남성 성선기능저하증 시장 규모 : 성선기능저하증 유형별
세계의 남성 성선기능저하증 시장 규모 : 병인별
세계의 남성 성선기능저하증 시장 규모 : 치료 유형별
세계의 남성 성선기능저하증 시장 규모 : 투여 경로별
세계의 남성 성선기능저하증 시장 규모 : 진단별
세계의 남성 성선기능저하증 시장 규모 : 최종사용자별
세계의 남성 성선기능저하증 시장 규모 : 유통 채널별
세계의 남성 성선기능저하증 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Male Hypogonadism Market size was valued at USD 1.65 Billion in 2024 and is poised to grow from USD 1.77 Billion in 2025 to USD 3.14 Billion by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).
The global male hypogonadism market encompasses the commercial landscape surrounding diagnostics, hormone replacement therapies, and supportive services for men suffering from low testosterone levels. This market is driven by the significant impact of hypogonadism on quality of life, cardiovascular health, and productivity. The introduction of innovative treatment options, such as transdermal gels and oral formulations, has spurred adoption and transformed this niche sector into a valuable realm for health stakeholders. Key growth factors include the integration of personalized medicine, which enhances product innovation and reimbursement strategies. Furthermore, AI-driven diagnostic automation is streamlining identification and management processes, leading to earlier interventions and better therapeutic outcomes. Consequently, this promotes demand for hormone-replacement products while providing cost-effective diagnostic solutions for healthcare systems.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Male Hypogonadism market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Male Hypogonadism Market Segments Analysis
Global male hypogonadism market is segmented by type of hypogonadism, etiology, treatment type, route of administration, diagnosis, end user, distribution channel and region. Based on type of hypogonadism, the market is segmented into Primary (Testicular) Hypogonadism, Secondary (Hypogonadotropic) Hypogonadism and Mixed/Combined Hypogonadism. Based on etiology, the market is segmented into Congenital Hypogonadism, Acquired Hypogonadism, Age-Related Late-Onset Hypogonadism, Drug-Induced Hypogonadism and Others. Based on treatment type, the market is segmented into Testosterone Replacement Therapy (TRT), Oral Testosterone Therapy, Injectable Testosterone Therapy, Transdermal Patches & Gels, Nasal Testosterone Therapy, Selective Estrogen Receptor Modulators (SERMs), Gonadotropin Therapy (hCG, hMG) and Others. Based on route of administration, the market is segmented into Oral, Intramuscular Injection, Transdermal, Nasal and Subcutaneous. Based on diagnosis, the market is segmented into Blood Testosterone Testing, Hormonal Panel, Genetic Testing, Imaging (MRI of Pituitary) and Others. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Fertility Clinics, Ambulatory Care Centers and Homecare Settings. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Male Hypogonadism Market
The rising awareness among the public regarding the symptoms associated with low testosterone levels has led to an increase in men seeking medical evaluations. This shift has resulted in higher diagnosis rates and a larger number of patients qualifying for hormone replacement therapy, consequently boosting the demand for pharmaceutical products and related healthcare services. Healthcare professionals now enjoy enhanced clarity in symptom recognition, which fosters more confident prescribing practices. Additionally, patient advocacy groups play a vital role by providing educational resources that promote open discussions about male hormonal health. This dynamic creates a positive feedback loop, promoting both awareness and treatment acceptance, ultimately supporting the ongoing growth of the global Male Hypogonadism market.
Restraints in the Global Male Hypogonadism Market
The high costs associated with testosterone replacement therapies, particularly long-acting injectables and transdermal systems, create significant financial challenges for many individuals, especially in areas lacking robust insurance coverage. This affordability issue often leads to high out-of-pocket expenses, discouraging patients from maintaining consistent treatment regimens and prompting healthcare providers to explore alternative, more budget-friendly options. Consequently, this cost sensitivity hampers overall market penetration, as clinicians may prioritize more economical prescribing practices. Additionally, pharmaceutical companies face obstacles in achieving growth in sales volume without implementing price reductions or value-based payment models, which ultimately limits market expansion and patient accessibility.
Market Trends of the Global Male Hypogonadism Market
The Global Male Hypogonadism market is witnessing a robust trend toward precision hormone therapy, characterized by personalized treatment approaches aligned with individual genetic profiles, symptom intensity, and lifestyle factors. Clinicians are increasingly adopting biomarker panels and digital monitoring technologies to optimize hormone replacement regimens, minimizing adverse effects and enhancing patient compliance. This shift is fostering collaborations among endocrinologists, fertility experts, and tech innovators, resulting in integrated care pathways that not only elevate patient satisfaction but also create new revenue opportunities for providers. Ultimately, this tailored treatment paradigm aims to significantly improve the overall quality of life for patients with hypogonadism.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Male Hypogonadism Market Size by Type of Hypogonadism & CAGR (2026-2033)
- Market Overview
- Primary (Testicular) Hypogonadism
- Secondary (Hypogonadotropic) Hypogonadism
- Mixed/Combined Hypogonadism
Global Male Hypogonadism Market Size by Etiology & CAGR (2026-2033)
- Market Overview
- Congenital Hypogonadism
- Acquired Hypogonadism
- Age-Related Late-Onset Hypogonadism
- Drug-Induced Hypogonadism
- Others
Global Male Hypogonadism Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Testosterone Replacement Therapy (TRT)
- Oral Testosterone Therapy
- Injectable Testosterone Therapy
- Transdermal Patches & Gels
- Nasal Testosterone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Gonadotropin Therapy (hCG, hMG)
- Others
Global Male Hypogonadism Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Intramuscular Injection
- Transdermal
- Nasal
- Subcutaneous
Global Male Hypogonadism Market Size by Diagnosis & CAGR (2026-2033)
- Market Overview
- Blood Testosterone Testing
- Hormonal Panel
- Genetic Testing
- Imaging (MRI of Pituitary)
- Others
Global Male Hypogonadism Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Fertility Clinics
- Ambulatory Care Centers
- Homecare Settings
Global Male Hypogonadism Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Male Hypogonadism Market Size & CAGR (2026-2033)
- North America (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
- US
- Canada
- Europe (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Endo International plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr Reddy's Laboratories Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clarus Therapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
